No Data
No Data
Yestar Healthcare Narrows Loss in 2023
Yestar Healthcare Holdings (HKG:2393) reported an attributable loss of 13.9 million yuan for the year ended Dec. 31, 2023, compared with a loss of 992.2 million yuan in the previous year, according to
巨星醫療控股:年度報告 2023
Yestar Healthcare Faces Second Arbitration Related to Trading Firm Acquisition
Yestar Healthcare Holdings (HKG:2393) received a notice of a second arbitration related to its acquisition of a 70% stake in Guangzhou Shengshiyuan Trading, according to a filing with the Hong Kong Ex
Superstar Healthcare Holdings (02393): Leung Chun-hung resigns as executive director
Superstar Medical Holdings (02393) announced that Leung Chun-hung undertakes other duties related to his future career and business development...
Superstar Medical Holdings (02393) announced annual results. Losses attributable to shareholders of 13.888 million yuan narrowed 98.6% year-on-year
According to the Zhitong Finance App, Superstar Medical Holdings (02393) announced its annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 2,913 billion yuan (RMB, same below) during the period, an increase of 3.86% over the previous year; losses attributable to shareholders were 13.888 million yuan, a year-on-year decrease of 98.6%; and a basic loss of 0.6 points per share. According to the announcement, demand for the Group's in vitro diagnostic consumables increased in 2023, mainly due to a sharp rise in demand for cardiomyocardial products from patients with diseases caused by COVID-19 in the first quarter of 2023. Receipts from continuing operations in this segment
YESTAR HEALTH: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
No Data